Masitinib mesylate

Research use only, not for human use.

A potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays.

A potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays; also inhibits Lyn, and to a lesser extent, FGFR3, and inhibits KIT gain-of-function mutants V559D (IC50=3.0 nM) and Δ27 mouse mutant (IC50=5 nM); dose-dependently inhibits SCF-induced cell proliferation in Ba/F3 cells expressing human wild-type KIT (IC50=150 nM); inhibits tumour growth in vivo.Prostate cancer Phase 3 Clinical.

——

——

AB1010 mesylate | AB-1010 mesylate | AB 1010 mesylate

Angiogenesis

c-Kit

c-Kit

Cancer

Prostate Cancer

1048007-93-7

594.748

C29H34N6O4S2

>98% (HPLC)

DMSO: ≥ 30 mg/mL

O=C(NC1=CC=C(C)C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C4=CC=C(CN5CCN(C)CC5)C=C4.OS(=O)(C)=O

Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-, methanesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years